Beyond Air CEO to speak at H.C. Wainwright Global Investment Conference.

Beyond Air, Inc. announced that CEO Steve Lisi will participate in the H.C. Wainwright 27th Annual Global Investment Conference, with an on-demand webcast available from September 5, 2025. Members of management will be available for investor meetings. Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve patient lives.

Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company specializing in nitric oxide (NO) therapy, has announced that CEO Steve Lisi will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held in New York, NY, from September 8-10, 2025 [1].

Lisi's participation in the conference provides an opportunity for investors to gain insights into Beyond Air's innovative medical devices and biopharmaceuticals. An on-demand webcast of the company's presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, on the H.C. Wainwright Conference platform [1]. Additionally, members of the management team will be available for one-on-one meetings with investors at the conference. Interested parties can contact their respective representatives at H.C. Wainwright to schedule these meetings.

Beyond Air is dedicated to harnessing the power of NO to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure [1]. Beyond Air is currently advancing other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM) [1].

The company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting [1].

Beyond Air's LungFit system is a cylinder-free, phasic flow generator and delivery system that can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. This system could potentially replace large, high-pressure NO cylinders, offering significant advantages in the hospital setting, including reduced inventory and storage requirements, improved safety, and operational benefits [1].

References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143497/0/en/Beyond-Air-to-Participate-in-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html